MacroGenics Management
Management criteria checks 2/4
MacroGenics' CEO is Eric Risser, appointed in Aug 2025, has a tenure of less than a year. total yearly compensation is $2.08M, comprised of 27% salary and 73% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $243.08K. The average tenure of the management team and the board of directors is 2.5 years and 8.5 years respectively.
Key information
Eric Risser
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 27.01% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 2.5yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Narrative Update • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Narrative Update • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking AlphaAnalysis Article • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
Narrative Update • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.Analysis Article • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.Analysis Article • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...Analysis Article • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
New Narrative • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.Analysis Article • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking AlphaAnalysis Article • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analysis Article • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking AlphaAnalysis Article • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking AlphaAnalysis Article • Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
With a price-to-sales (or "P/S") ratio of 5.4x MacroGenics, Inc. ( NASDAQ:MGNX ) may be sending very bullish signals at...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$562k | -US$75m |
| Sep 30 2025 | n/a | n/a | -US$76m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$56m |
| Dec 31 2024 | n/a | n/a | -US$67m |
| Sep 30 2024 | n/a | n/a | -US$98m |
| Jun 30 2024 | n/a | n/a | -US$136m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | n/a | n/a | -US$9m |
| Sep 30 2023 | n/a | n/a | US$50m |
| Jun 30 2023 | n/a | n/a | US$7m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$2m | US$461k | -US$120m |
| Sep 30 2022 | n/a | n/a | -US$191m |
| Jun 30 2022 | n/a | n/a | -US$219m |
| Mar 31 2022 | n/a | n/a | -US$217m |
| Dec 31 2021 | US$2m | US$428k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$146m |
| Jun 30 2021 | n/a | n/a | -US$129m |
| Mar 31 2021 | n/a | n/a | -US$136m |
| Dec 31 2020 | US$1m | US$431k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$158m |
| Jun 30 2020 | n/a | n/a | -US$167m |
| Mar 31 2020 | n/a | n/a | -US$152m |
| Dec 31 2019 | US$2m | US$388k | -US$152m |
Compensation vs Market: Eric's total compensation ($USD2.08M) is above average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
CEO
Eric Risser (52 yo)
less than a year
Tenure
US$2,078,854
Compensation
Mr. Eric Blasius Risser is President, Chief Executive Officer and Director at MacroGenics, Inc. since August 13, 2025. He served as Chief Operating Officer at MacroGenics, Inc. since February 22, 2022 unti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.08m | 0.12% $ 243.1k | |
| Senior VP | 18yrs | US$1.15m | 0.32% $ 649.0k | |
| Senior VP of Research & Chief Scientific Officer | 9.7yrs | US$1.22m | 0.23% $ 459.3k | |
| Senior Vice President of Technical Operations | 3.5yrs | US$1.88m | 0.061% $ 121.4k | |
| Senior VP | 8.9yrs | no data | 0.049% $ 98.0k | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Business Development & Portfolio Planning | less than a year | no data | no data | |
| Vice President & Interim Head of Clinical Development | less than a year | no data | no data | |
| VP, Controller & Treasurer | 1.5yrs | no data | 0.020% $ 40.3k |
2.5yrs
Average Tenure
58yo
Average Age
Experienced Management: MGNX's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.08m | 0.12% $ 243.1k | |
| Independent Director | 12.7yrs | US$95.86k | 0.017% $ 34.7k | |
| Independent Director | 5.3yrs | US$110.48k | 0.017% $ 34.7k | |
| Independent Director | 21.6yrs | US$85.86k | 0.069% $ 138.8k | |
| Independent Director | 3.3yrs | US$85.86k | 0.017% $ 34.7k | |
| Director | 24.7yrs | US$969.84k | 1.36% $ 2.7m | |
| Independent Chairman of the Board | 4yrs | US$145.03k | 0.17% $ 349.7k | |
| Independent Director | 3.3yrs | US$80.22k | 0.017% $ 34.7k | |
| Independent Director | 9.3yrs | US$81.91k | 0.017% $ 34.7k | |
| Independent Director | 8.5yrs | US$106.28k | 0.017% $ 34.7k | |
| Independent Director | 9.3yrs | US$85.86k | 0.017% $ 34.7k |
8.5yrs
Average Tenure
67yo
Average Age
Experienced Board: MGNX's board of directors are considered experienced (8.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 05:35 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MacroGenics, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |